Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.
Hidenori SakaiYusuke MiyazakiShingo NakayamadaYasuyuki TodorokiKentaro HanamiShunsuke FukuyoAyako YamaguchiIppei MiyagawaMasanobu UenoHiroaki TanakaYasuyuki TodorokiNaoaki OhkuboMasashi FunadaSatsuki MatsunagaYoshiya TanakaPublished in: Rheumatology (Oxford, England) (2024)
BEL, in addition to SoC, controls disease activity, reduces GC use, and suppresses organ damage in case of proliferative LN. Earlier BEL induction within 6 weeks may help achieve CRR in treatment-resistant cases without eGFR improvement at 4 weeks after induction therapy.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- end stage renal disease
- ankylosing spondylitis
- small cell lung cancer
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- chronic kidney disease
- signaling pathway
- gestational age
- oxidative stress
- epidermal growth factor receptor
- tyrosine kinase
- mesenchymal stem cells
- high resolution
- preterm birth
- gas chromatography